ANL 13.55 Decreased By ▼ -0.79 (-5.51%)
ASC 13.32 Decreased By ▼ -0.63 (-4.52%)
ASL 14.02 Decreased By ▼ -1.08 (-7.15%)
BOP 8.36 Decreased By ▼ -0.16 (-1.88%)
BYCO 6.14 Decreased By ▼ -0.40 (-6.12%)
FCCL 17.61 Decreased By ▼ -1.19 (-6.33%)
FFBL 24.90 Decreased By ▼ -1.95 (-7.26%)
FFL 10.25 Decreased By ▼ -0.75 (-6.82%)
FNEL 9.80 Decreased By ▼ -0.71 (-6.76%)
GGGL 15.30 Decreased By ▼ -0.95 (-5.85%)
GGL 29.50 Decreased By ▼ -2.00 (-6.35%)
HUMNL 5.90 Decreased By ▼ -0.34 (-5.45%)
JSCL 16.00 Decreased By ▼ -0.89 (-5.27%)
KAPCO 32.05 Decreased By ▼ -1.05 (-3.17%)
KEL 3.17 Decreased By ▼ -0.10 (-3.06%)
MDTL 2.21 Decreased By ▼ -0.06 (-2.64%)
MLCF 34.39 Decreased By ▼ -2.71 (-7.3%)
NETSOL 95.50 Decreased By ▼ -7.30 (-7.1%)
PACE 4.25 Decreased By ▼ -0.43 (-9.19%)
PAEL 21.43 Decreased By ▼ -1.72 (-7.43%)
PIBTL 7.60 Decreased By ▼ -0.26 (-3.31%)
POWER 6.60 Decreased By ▼ -0.45 (-6.38%)
PRL 12.69 Decreased By ▼ -0.97 (-7.1%)
PTC 8.75 Decreased By ▼ -0.15 (-1.69%)
SILK 1.25 Decreased By ▼ -0.06 (-4.58%)
SNGP 38.68 Decreased By ▼ -3.02 (-7.24%)
TELE 15.88 Decreased By ▼ -1.11 (-6.53%)
TRG 81.73 Decreased By ▼ -6.02 (-6.86%)
UNITY 23.70 Decreased By ▼ -1.65 (-6.51%)
WTL 2.05 Decreased By ▼ -0.15 (-6.82%)
BR100 4,400 Decreased By ▼ -271.31 (-5.81%)
BR30 17,500 Decreased By ▼ -1334.18 (-7.08%)
KSE100 43,129 Decreased By ▼ -2240.33 (-4.94%)
KSE30 16,655 Decreased By ▼ -920.94 (-5.24%)

Coronavirus
LOW Source: covid.gov.pk
Pakistan Deaths
28,745
824hr
Pakistan Cases
1,285,631
37724hr
0.85% positivity
Sindh
476,017
Punjab
443,240
Balochistan
33,488
Islamabad
107,765
KPK
180,146
World

Sinopharm's COVID-19 vaccine remained active against S.Africa variant, effect reduced - lab study

  • Variants of the virus have stirred concern that they might weaken effects of vaccines and treatments developed prior to their emergence.
03 Feb 2021

Two COVID-19 vaccines from Chinese companies including Sinopharm triggered immunity against a highly transmissible coronavirus variant first found in South Africa, but their effect appeared weaker, a small-sample lab study released on Tuesday showed.

Variants of the virus have stirred concern that they might weaken effects of vaccines and treatments developed prior to their emergence.

Twelve serum samples each taken from recipients of two vaccines developed by a subsidiary of China National Pharmaceutical Group (Sinopharm) and a unit of Chongqing Zhifei Biological Products retained neutralising activity against the South African variant, their researchers said in a paper.

The paper was written by researchers from Sinopharm-affiliated Beijing Institute of Biological Products, the Institute of Microbiology of Chinese Academy of Sciences, which is co-developing a candidate with Zhifei unit, and two other Chinese agencies.

However, the samples' activity against the variant was weaker than against the original virus and another variant currently spreading globally, according to the paper published on website BioRxiv ahead its peer-review. bit.ly/3rfr2UZ

The activity reduction “should be taken into account for its impact for the clinical efficacy of these vaccines,” they said. The Sinopharm vaccine is approved in China for general public use and is also used in several other countries including the United Arab Emirates. The Zhifei shot is in late-stage clinical trials in China and overseas.

Preliminary clinical trial data on vaccines from Novavax Inc and Johnson & Johnson also showed they were significantly less effective at preventing COVID-19 in trial participants in South Africa, where the potent new variant is widespread.

We love hearing your feedback, please help us improve by answering these few survey questions

Comments

Comments are closed.